FDA支持公司在非临床可比性方面的努力 - FDA允许公司即刻使用圣地亚哥制造设施[1] - FDA同意公司在洛杉矶和圣地亚哥两个不同设施生产的药物产品之间的可比性已经得到证实[4] FDA建议公司在即将举行的第二季度B类会议上讨论预BLA会议和滚动BLA提交 - 公司计划在第二季度与FDA分享HOPE-2开放标签延伸（OLE）3年安全性和疗效数据[3]

CAPR股票价格分析 - CAPR过去四周股价上涨11.9%，收盘价为$6.60，根据华尔街分析师的短期价格目标，股票仍有潜在上涨空间[1] - 分析师的平均预测为$21，意味着潜在上涨幅度为218.2%，其中包括四个短期价格目标，最低为$8，最高为$40，标准偏差为$14.38[2] 投资决策建议 - 一致的价格目标虽然备受投资者追捧，但仅凭此指标做投资决策可能不明智，因为分析师设定价格目标的能力和公正性一直存在质疑[3] - CAPR的强劲平均价格目标并不是潜在上涨的唯一指标，分析师对公司能够报告比他们先前预测的更好的收益的强烈一致意见加强了这一观点[4]

Capricor Therapeutics - Capricor Therapeutics是一家生物技术公司，致力于开发用于治疗和预防罕见疾病的转化性细胞和外泌体疗法[3] - 公司的首席执行官将在即将举行的投资者会议上介绍CAP-1002用于治疗杜兴氏肌营养不良症（DMD）的最新进展[2] - Capricor与Nippon Shinyaku Co., Ltd.（美国子公司：NS Pharma, Inc.）达成合作伙伴关系，独家在美国和日本进行CAP-1002的商业化和分销，但CAP-1002仍为新药，尚未获得批准[5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K þ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-34058 CAPRICOR THERAPEUTICS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 88-0363465 (State or other jurisdiction of (I ...

Shares of Capricor Therapeutics (CAPR) have gained 32.6% over the past four weeks to close the last trading session at $5.19, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $18.75 indicates a potential upside of 261.3%. The mean estimate comprises four short-term price targets with a standard deviation of $14.45. While the lowest estimate of $8 indicates a 54.1% increase from t ...

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company will present the positive 24-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD) at this year's MDA Clinical and Scientific Conference which is taking place in Orland ...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET Company Participants AJ Bergmann - Chief Financial Officer Linda Marban - Chief Executive Officer Conference Call Participants Joseph Pantginis - H.C. Wainright Kristen Kluska - Cantor Fitzgerald Aydin Huseynov - Ladenburg Operator Good afternoon, ladies and gentlemen, and welcome to Capricor Therapeutics Fourth Quarter 2023 Earnings Call. At this time, all lines are in listen-only mode. Following the pre ...

财务状况 - Capricor Therapeutics在2023年第四季度和全年财务报告中显示，公司现金、现金等价物和可市场证券总额约为3950万美元[18] - Capricor Therapeutics第四季度2023年的营收约为1210万美元，较2022年同期的约100万美元有显著增长[21] - Capricor Therapeutics第四季度2023年的总营业费用约为1320万美元，较2022年同期的约900万美元有增长[22] - Capricor Therapeutics第四季度2023年净亏损约为80万美元，每股亏损为0.02美元，较2022年同期的净亏损约770万美元，每股亏损为0.31美元有显著减少[23] - Capricor Therapeutics预计根据当前运营计划和财务资源，其现金、现金等价物和可市场证券将足以覆盖到2025年第一季度的预期支出和资本需求[24] 公司业绩 - Capricor在2023年第四季度实现了1,208.8万美元的营收，同比增长116.1%[32] - Capricor在2023年第四季度的研发支出为994.0万美元，同比增长59.6%[32] - Capricor在2023年第四季度的总资产达到5,873.4万美元，较上年同期增长17.3%[32]

SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- – Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company has been granted an in-person Type-B meeting with the U.S. Food & Drug Administration (FDA) scheduled for late March. In the upcoming meeting with the FDA, the Company intends to discuss its proposed chemistry, manufacturing and controls (CMC) plans for comm ...

-Project NextGen Collaboration will Support Capricor's StealthX™ Exosome Platform and Provide Non- Dilutive Support for Advancement into the Clinic- SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced that Capricor's proprietary StealthX™ exosome-based multivalent vaccine (StealthX™ vaccine) for the prevention of SARS-CoV-2 has ...